CG
PETX

Cutler Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Cutler Group’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,400
Closed -$5K – 7174
2017
Q2 		$5K Sell
12,400
-5,500
-31% -$33.8K ﹤0.01% 4942
2017
Q1 		$18K Buy
+17,900
New +$121K ﹤0.01% 3466
2016
Q4 		– Sell
-6,100
Closed -$3K – 7756
2016
Q3 		$3K Buy
6,100
+100
+2% +$830 ﹤0.01% 5539
2016
Q2 		$12K Buy
6,000
+4,700
+362% +$30.2K ﹤0.01% 3980
2016
Q1 		$3K Buy
+1,300
New +$4.89K ﹤0.01% 5404

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cutler Group's PETX Position: Q3 2018 in Review

Cutler Group sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2018, closing a stake of 100 shares.

Cutler Group first reported a position in PETX in Q1 2016 and held it in 8 quarters. The position peaked at $17K in Q3 2016. 100 funds tracked by Wall St. Rank hold PETX as of Q3 2018.

  • Cutler Group reported no remaining Aratana Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Cutler Group sold 100 Aratana Therapeutics, Inc. shares in Q3 2018.
  • Cutler Group first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
  • Cutler Group's Aratana Therapeutics, Inc. position peaked at $17K in Q3 2016.
  • 100 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2018.

Based on Cutler Group's 13F filing for Q3 2018, filed 7 Nov 2018.